-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
-
Multiple Institutions Welcome Renowned Lung Cancer Experts
Dartmouth Cancer Center and Temple Health announce incoming directors following the appointment of a new division chief of thoracic medical oncology at City of Hope earlier this year.
-
Tobacco Endgame: A Critical Frontier for Lung Cancer Prevention and Equity
Drs. Babalola Faseru and Carolyn Dresler outline strategies to shift the paradigm from tobacco control to tobacco elimination, including expanded cessation and early-detection infrastructure.
-
Under Therapeutic Pressure: ELCC Session Highlights How Tumor Switching is Reshaping the Treatment Landscape
Experts emphasize the need for multidisciplinary approaches, personalized therapies, and strategies to address intratumor heterogeneity.
-
Don’t Go Breaking My Heart: Cardiac Toxicity Prevention in Lung Cancer and Management Through Multidisciplinary Care
Dr. Arya Amini highlights several guidelines that can inform cardiac surveillance care for patients with lung cancer following completion of radiation treatment.
-
Rescission of EPA Finding Prompts Concern About Impacts on Cancer Care
Experts, including Dr. Joan H. Schiller, warn of devastating impacts to public health and the environment after the US government shuts down federal efforts to curb greenhouse gas emissions.
-
Keynote Address Explores the Future of Biomarkers in the ADC Era
During his lecture at the 2026 European Lung Cancer Congress, Dr. Fred R. Hirsch outlined the current state of knowledge in ADC research, as well as what still needs to be learned.
-
Dose Escalation Trial Yields Encouraging Results for SCLC With DLL3 Expression
Dr. Julien Mazières reported that while obrixtamig plus ezabenlimab showed encouraging responses at the clinically effective dose, efficacy peaked at the highest dose, reaching an ORR of 58% and a DCR of 83%.
-
Final Results From the ETOP ADEPPT Trial Show Promise for Two Underrepresented Patient Populations
The findings, presented by Dr. Jarushka Naidoo at ELCC 2026, demonstrated that treatment with adagrasib was effective in fit patients aged 70 years and older with KRAS G12C-mutant NSCLC and provided quality-of-life benefits for those with poor performance status.
-
European Framework Aims to Provide Guidance on the Development, Clinical Applicability of AI-Based Biomarkers
During ELCC 2026, Dr. Mihaela Aldea discussed how the ESMO requirements can be used to validate AI-driven biomarkers, while emphasizing the importance of continuous post-validation monitoring for data drift.
-
A Shift in Focus: Real-World Data Reframe the Value of N1 Nodal Assessments in Resection
Dr. Christopher Seder explores how a more extensive N1 station assessment allows thoracic oncologists and pathologists to find more unrecognized cancer and improve staging accuracy.